HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study

REFERENCES

• Pinkerton CR, Bataillard A, Guillo S, . Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer. 2001;37:1338–1344.
   PubMedGoogle Scholar
• Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003;40:276–287.
   PubMedGoogle Scholar
• Burdach S, Jurgens H. High-dose chemotherapy (HDC) in the Ewing family of tumors (EFT). Crit Revi Oncol Hematol. 2002;41:169–189.
   PubMed Web of Science ®Google Scholar
• Kutluk MT, Yalcin B, Akyuz C, . Treatment results and prognostic factors in Ewing sarcoma. Pediatr Hematol Oncol. 2004;21:597–610.
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Ahrens S, Paulussen M, . Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;17:3108–3114.
   Google Scholar
• Huang HY, Illei PB, Zhao Z, . Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005;23:548–558.
   PubMed Web of Science ®Google Scholar
• Yaniv I, Cohen IJ, Stein J, . Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer. 2004;42:404–409.
   PubMed Web of Science ®Google Scholar
• Eralp Y, Bavbek S, Basaran M, . Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. Am J Clin Oncol. 2002;25:418–424.
   PubMedGoogle Scholar
• Oberlin O, Deley MC, Bui BN, . Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–1654.
   PubMed Web of Science ®Google Scholar
• Laurence V, Pierga JY, Barthier S, . Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol. 2005;28:301–309.
   PubMed Web of Science ®Google Scholar
• Madero L, Muñoz A, Sanchez de Toledo J, . Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplant. 1998;21:795–799.
   Google Scholar
• Ritchie DS, Grigg AP, Roberts W, . Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. Intern Med J. 2004;34:431–434.
   Google Scholar
• Burdach S, van Kaick B, Laws HJ, . Allogeneic and autologous stem cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of European Intergroup study EICESS. Stem-cell transplant programs at Dusseldorf University Medical Center, Germany, and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451–1462.
   Google Scholar
• Horowitz ME, Kinsella TJ, Wexler LH, . Total body irradiation and autologous bone marrow transplant in the treatment of high risk Ewing's sarcoma and rhabdomiosarcoma. J Clin Oncol. 1993;11:1911–1918.
   PubMed Web of Science ®Google Scholar
• Hartmann O, Oberlin O, Beaujean F, . Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children. Bull Cancer. 1990;77:181–187.
   PubMed Web of Science ®Google Scholar
• Burdach S, Jurgens H, Peters C, . Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482–1488.
   PubMed Web of Science ®Google Scholar
• Marcus RB, Graham-Pole JR, Springfield DS, . High-risk Ewing's sarcoma: end-intensification using autologous bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1988;15:53–59.
   PubMed Web of Science ®Google Scholar
• Diaz MA, Gonzalez-Vicent M, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant. 1999;24:1157–1159.
   PubMed Web of Science ®Google Scholar
• Atra A, Whelan JS, Calvagna V, . High-dose busulfan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant. 1997;20:843–846.
   PubMed Web of Science ®Google Scholar
• Hawkins D, Barnett T, Bensinger W, . Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor risk Ewing sarcoma family tumors. Med Pediatr Oncol. 2000;34:328–337.
   PubMedGoogle Scholar
• Diaz MA, Villa M, Alegre A, . Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancies. Br J Haematol. 1996;94:148–154.
   PubMed Web of Science ®Google Scholar
• Diaz MA, Alegre A, Villa M, . Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics. Bone Marrow Transplant. 1996;18:699–703.
   PubMed Web of Science ®Google Scholar
• Diaz MA, García-Sanchez F, Lillo R, . Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. Haematologica. 1999;84:30–33.
   Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187–220.
   Google Scholar
• Kasper B, Lehnert T, Bernd L, . High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft tissue sarcomas. Bone Marrow Transplant. 2004;34:37–41.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Lasset C, Pinkerton R, . Impact of megatherapy in children with high-risk Ewing's tumor in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 1995;15:697–705.
   PubMed Web of Science ®Google Scholar
• Paulussen M, Ahrens S, Burdach S, . Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9:275–281.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Krailo MD, Ladanyi M, . High-dose melphalan, etoposide, total body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812–2820.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Matsunobu T, Sakamoto A, . High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors. J Orthop Sci. 2002;7:477–482.
   Google Scholar
• Stewart DA, Gyonyor E, Paterson AH, . High-dose melphalan ± total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant. 1996;18:315–318.
   PubMed Web of Science ®Google Scholar
• Verrill MW, Judson IR, Harmer CL, . Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol. 1997;15:2611–2621.
   PubMed Web of Science ®Google Scholar
• Paulussen M, Ahrens S, Lehnert M, . Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol. 2001;12:1619–1630.
   PubMed Web of Science ®Google Scholar
• Dunst J, Ahrens S, Paulussen M, . Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys. 1998;42:379–384.
   PubMed Web of Science ®Google Scholar
• Gardner SL, Carreras J, Boudreau C, . Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant. 2008;41:867–872.
   Google Scholar